These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31272741)

  • 1. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials.
    Haberkamp M; Moseley J; Athanasiou D; de Andres-Trelles F; Elferink A; Rosa MM; Magrelli A
    Neuromuscul Disord; 2019 Jul; 29(7):514-516. PubMed ID: 31272741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
    Servais L; Yen K; Guridi M; Lukawy J; Vissière D; Strijbos P
    J Neuromuscul Dis; 2022; 9(2):335-346. PubMed ID: 34958044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.
    Servais L; Camino E; Clement A; McDonald CM; Lukawy J; Lowes LP; Eggenspieler D; Cerreta F; Strijbos P
    Digit Biomark; 2021; 5(2):183-190. PubMed ID: 34723071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
    Romano A; Favetta M; Schirinzi T; Summa S; Minosse S; D'Amico A; Catteruccia M; Petrarca M; Castelli E; Bertini E; Vasco G
    Neuromuscul Disord; 2019 Dec; 29(12):920-929. PubMed ID: 31791868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal community walking activity in Duchenne muscular dystrophy.
    Fowler EG; Staudt LA; Heberer KR; Sienko SE; Buckon CE; Bagley AM; Sussman MD; McDonald CM
    Muscle Nerve; 2018 Mar; 57(3):401-406. PubMed ID: 28692198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of muscular co-activation and gait variability in children with Duchenne muscular dystrophy: A 2-year follow-up study.
    Rinaldi M; Petrarca M; Romano A; Vasco G; D'Anna C; Bibbo D; Schmid M; Castelli E; Conforto S
    Clin Biomech (Bristol, Avon); 2020 Aug; 78():105101. PubMed ID: 32652381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gait deviations in Duchenne muscular dystrophy-Part 1. A systematic review.
    Goudriaan M; Van den Hauwe M; Dekeerle J; Verhelst L; Molenaers G; Goemans N; Desloovere K
    Gait Posture; 2018 May; 62():247-261. PubMed ID: 29579701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study.
    Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H
    J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials.
    Chrzanowski SM; Darras BT; Rutkove SB
    Neurotherapeutics; 2020 Jan; 17(1):142-152. PubMed ID: 31879850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Reliability of the Functional Evaluation Scale for Duchenne Muscular Dystrophy, Gait Domain: A Pilot Study.
    de Carvalho EV; Hukuda ME; Escorcio R; Voos MC; Caromano FA
    Physiother Res Int; 2015 Sep; 20(3):135-46. PubMed ID: 25521365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a wearable device to assess sleep and motor function in Duchenne muscular dystrophy.
    Siegel BI; Cakmak A; Reinertsen E; Benoit M; Figueroa J; Clifford GD; Phan HC
    Muscle Nerve; 2020 Feb; 61(2):198-204. PubMed ID: 31725915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy.
    Goudriaan M; Van den Hauwe M; Simon-Martinez C; Huenaerts C; Molenaers G; Goemans N; Desloovere K
    Gait Posture; 2018 Jun; 63():159-164. PubMed ID: 29751322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.